var data={"title":"Nontyphoidal Salmonella bacteremia","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Nontyphoidal Salmonella bacteremia</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/contributors\" class=\"contributor contributor_credentials\">Elizabeth L Hohmann, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/contributors\" class=\"contributor contributor_credentials\">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/contributors\" class=\"contributor contributor_credentials\">Allyson Bloom, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 10, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nontyphoidal salmonellae are an important bacterial cause of diarrheal disease. The epidemiology and pathophysiology of nontyphoidal strains differ from typhoidal strains [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=epidemiology-microbiology-clinical-manifestations-and-diagnosis-of-enteric-typhoid-and-paratyphoid-fever\" class=\"medical medical_review\">&quot;Epidemiology, microbiology, clinical manifestations, and diagnosis of enteric (typhoid and paratyphoid) fever&quot;</a>.)</p><p>Issues related to the epidemiology, clinical microbiology, clinical manifestations, and treatment of nontyphoidal Salmonella bacteremia will be reviewed here. Nontyphoidal Salmonella gastrointestinal disease and typhoid fever are discussed in detail separately. (See <a href=\"topic.htm?path=nontyphoidal-salmonella-gastrointestinal-infection-and-carriage\" class=\"medical medical_review\">&quot;Nontyphoidal Salmonella: Gastrointestinal infection and carriage&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-enteric-typhoid-and-paratyphoid-fever\" class=\"medical medical_review\">&quot;Treatment and prevention of enteric (typhoid and paratyphoid) fever&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span></p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Incidence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bacteremia and other forms of extraintestinal Salmonella infection are serious complications that may not be suspected in the setting of mild primary infection. The burden varies geographically. In a systematic review that extrapolated the global incidence of invasive nontyphoidal Salmonella infections based on 10 studies, there were an estimated 49 cases per 100,000 people worldwide in 2010 [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/2\" class=\"abstract_t\">2</a>]. The greatest burden was in Africa, which had an estimated incidence of 227 cases per 100,000 people. Approximately 65 percent of cases worldwide are in children younger than five years.</p><p>It is estimated that perhaps 1 percent of enteric infections with nontyphoidal Salmonella result in bacteremia, but the true rate of bacteremia is unknown, as many primary enteric infections are mild or not microbiologically diagnosed.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Risk factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Factors affecting the incidence of bacteremia include Salmonella serotype, geographic location, time of year, and host factors. Host risk factors for nontyphoidal Salmonella bacteremia include extremes of age and chronic or immunosuppressing conditions, including malignancy, rheumatological disease, TNF blockade (eg, agents such as <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> or <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a>), transplantation, HIV infection, and congenital immune defects [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/3-6\" class=\"abstract_t\">3-6</a>]. Other predisposing comorbidities include liver disease, hemoglobinopathies (especially sickle cell disease), schistosomiasis, and chronic granulomatous disease. Alteration of the GI tract also predisposes to progression from enteric to systemic salmonellosis (eg, by suppression of gastric acid, malnutrition, recent antibiotic use, or rotavirus infection) [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/7\" class=\"abstract_t\">7</a>]. (See <a href=\"topic.htm?path=pathogenesis-of-salmonella-gastroenteritis\" class=\"medical medical_review\">&quot;Pathogenesis of Salmonella gastroenteritis&quot;</a>.)</p><p>In a series of 55 Malaysian adults with nontyphoidal Salmonella bacteremia, over 90 percent of patients had an underlying medical illness; 65 percent had severe immunosuppression, most commonly HIV infection or malignancy [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/8\" class=\"abstract_t\">8</a>]. In sub-Saharan Africa, nontyphoidal Salmonella bacteremia is a leading cause of bacteremia in adults and children [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/8-13\" class=\"abstract_t\">8-13</a>]. Invasive disease in Africa may be linked to malaria transmission [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/14\" class=\"abstract_t\">14</a>], possibly related to increased intestinal permeability and bacterial translocation in the setting of malaria [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/15,16\" class=\"abstract_t\">15,16</a>]. In these areas, nontyphoidal Salmonella bacteremia may occur in epidemic waves and mortality may be very high. The average case fatality rate of bacteremic illness was 19 percent in one meta-analysis of African reports [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/17\" class=\"abstract_t\">17</a>]. Relapsing bacteremia and higher mortality are observed in the setting of concurrent HIV infection.</p><p>Children with nontyphoidal bacteremia in resource-rich settings usually have associated gastroenteritis, do not typically have underlying comorbid illness, and most recover uneventfully [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/7,18,19\" class=\"abstract_t\">7,18,19</a>]. In a series of 144 pediatric cases of nontyphoidal Salmonella bacteremia in Pittsburgh (median age 10.5 months), 82 percent of patients were previously healthy [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/18\" class=\"abstract_t\">18</a>]. </p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">MICROBIOLOGY AND DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Blood cultures should be drawn in patients with Salmonella gastroenteritis ill enough to require hospitalization. Nontyphoidal Salmonella are vigorous organisms that grow readily in aerobic and anaerobic blood culture bottles.</p><p>Serotype distribution varies greatly by location and over time. S. enteritidis and S. typhimurium are the most commonly isolated pathogenic serotypes; therefore, they are also most frequently isolated from the blood. Some less frequently isolated serotypes can be more invasive than others and are more likely to cause bacteremia (including S. enterica serotypes Dublin, Choleraesuis, Virchow, Infantis, Newport, and Heidelberg) [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/1,20\" class=\"abstract_t\">1,20</a>]. (See <a href=\"topic.htm?path=nontyphoidal-salmonella-microbiology-and-epidemiology\" class=\"medical medical_review\">&quot;Nontyphoidal Salmonella: Microbiology and epidemiology&quot;</a>.)</p><p>A &quot;primary bacteremia&quot; (ie, a positive blood culture in the absence of recent or current gastrointestinal symptoms of Salmonella infection) may be an initial signal of unappreciated immunological dysfunction. HIV infection should be considered; recurrent Salmonella infection was a relatively frequent AIDS-defining infection in the US prior to the availability of potent antiretroviral therapy (ART). Other more frequently encountered co-morbidities include malignancy, diabetes, and rheumatologic illness. Therapeutic immunosuppression with steroids and other immunomodulatory drugs is increasingly common.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">COMPLICATIONS</span></p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Extraintestinal focal infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nontyphoidal salmonellae bacteremia can progress to development of infection at any site, including the urinary tract, lung, pleura, heart, long bones, joints, muscle, and central nervous system. After stool and blood, urinary isolates are encountered most frequently; these may reflect urologic abnormalities, bacteremia in the setting of chronic medical illness, <span class=\"nowrap\">and/or</span> retrograde spread of infection [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/21,22\" class=\"abstract_t\">21,22</a>].</p><p>In a case series of 229 children from an urban setting in Thailand with invasive salmonellosis, respiratory symptoms were surprisingly common (in about 25 percent) [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/23\" class=\"abstract_t\">23</a>]. These and underlying hepatobiliary disease were associated with an increased risk of fatality. </p><p>Salmonella meningitis is a rare complication that typically occurs in neonates and children &le;1 year; for this reason, any form of nontyphoidal salmonellosis in infants should prompt immediate and attentive management [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/24,25\" class=\"abstract_t\">24,25</a>]. Where HIV prevalence is high, nontyphoidal salmonella meningitis can also be seen in adults [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/26\" class=\"abstract_t\">26</a>]. Mortality is high and survivors may not have complete neurological recovery. (See <a href=\"topic.htm?path=gram-negative-bacillary-meningitis-treatment\" class=\"medical medical_review\">&quot;Gram-negative bacillary meningitis: Treatment&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Endovascular infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Endovascular infection is an uncommon but serious complication of nontyphoidal Salmonella bacteremia. Initially noted in the 1970s, subsequent population-based studies have noted that approximately 10 to 20 percent of adults over 50 years of age with documented nontyphoidal Salmonella bloodstream infections have a suppurative endovascular focus of infection [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/27,28\" class=\"abstract_t\">27,28</a>]. The organisms are presumed to home to existing atherosclerotic sites in large vessels in older adults; this is the rationale for a more aggressive approach to treatment of Salmonella gastroenteritis in older individuals. (See <a href=\"topic.htm?path=nontyphoidal-salmonella-gastrointestinal-infection-and-carriage\" class=\"medical medical_review\">&quot;Nontyphoidal Salmonella: Gastrointestinal infection and carriage&quot;</a>.)</p><p>Endovascular infection was specifically linked to atherosclerosis in one Taiwanese study, in the absence of other clinical features or immunodeficiencies [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/29\" class=\"abstract_t\">29</a>]. The abdominal aorta (especially infrarenal) is the most frequent site of vascular infection, though involvement of the thoracic aorta, other central arterial sites and endocarditis occur as well [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/30\" class=\"abstract_t\">30</a>]. Subacute fever and abdominal and back pain are the typical presenting symptoms; a pulsatile mass is a late and ominous finding.</p><p>The diagnostic approach should consist of CT or MRI (preferably with contrast angiographic analysis) when an aortic or vascular focus is possible or suspected. </p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Extraintestinal nontyphoidal Salmonella infections generally require surgical drainage or debridement and prolonged antimicrobial therapy.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Antibiotic selection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Fluoroquinolones are a reasonable empiric antibiotic choice for treatment of nontyphoidal Salmonella bacteremia (<a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> 400 mg intravenously twice daily or <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> 500 to 750 mg intravenously once daily). Fluoroquinolones have excellent intracellular penetration and oral bioavailability, allowing transition to oral therapy with clinical improvement. </p><p>Fluoroquinolones are frequently avoided in children because of cartilage abnormalities observed in developing animals, although data suggest that fluoroquinolones may be used in children over short courses [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/31\" class=\"abstract_t\">31</a>]. Treatment of serious Salmonella infections is a reasonable indication for use of fluoroquinolones in children, especially if other agents are not readily available [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/32\" class=\"abstract_t\">32</a>]. (See <a href=\"topic.htm?path=fluoroquinolones\" class=\"medical medical_review\">&quot;Fluoroquinolones&quot;</a>.)</p><p>Third generation cephalosporins are a reasonable alternative to fluoroquinolones (eg, <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a> 1 to 2 g intravenously once daily or <a href=\"topic.htm?path=cefotaxime-drug-information\" class=\"drug drug_general\">cefotaxime</a> 2 g intravenously every eight hours).</p><p>Other reasonable antibiotic alternatives include <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> (8 to 10 <span class=\"nowrap\">mg/kg/day</span> of the <a href=\"topic.htm?path=trimethoprim-drug-information\" class=\"drug drug_general\">trimethoprim</a> component divided three times per day) and <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">ampicillin</a> (2 g IV every 4 hours).</p><p>Reduced susceptibility and frank resistance to fluoroquinolones and third generation cephalosporins is increasing [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/33,34\" class=\"abstract_t\">33,34</a>]. Resistance has been reported frequently in Asia and history of travel to this region should be considered in clinical management [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/35\" class=\"abstract_t\">35</a>]. In the United States, the number of ceftriaxone-resistant blood isolates has approximately doubled, from 2.5 percent (1996 to 2007) to approximately 5 percent (2003 to 2013), as reported to the Centers for Disease Control and Prevention's National Antimicrobial Resistance Monitoring System [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/36\" class=\"abstract_t\">36</a>]. Importantly, these resistance patterns correlate with findings in ground beef, cattle, and poultry [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/37\" class=\"abstract_t\">37</a>]. </p><p>Antibiotics must be tailored to susceptibility data once available, and infectious disease consultation may be helpful. Although nalidixic acid disc resistance screening had been previously used as a marker for relative resistance to fluoroquinolones, direct testing for sensitivity to <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> or other clinically used fluoroquinolones is now recommended, when possible, for cases of invasive salmonellosis [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/34\" class=\"abstract_t\">34</a>]. Break points for susceptibility have been lowered such that fully-fluoroquinolone susceptible organisms are now defined as those with a minimum inhibitory concentration (MIC) of 0.06 <span class=\"nowrap\">mcg/mL</span> or less. </p><p>Nalidixic acid resistance testing does not detect all mechanisms of fluoroquinolone resistance. </p><p>For management of infections due to highly resistant organisms, infectious disease consultation is advisable. Carbapenems are appropriate agents for treatment of infection due to highly resistant organisms [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/38,39\" class=\"abstract_t\">38,39</a>]; resistance to carbapenems has rarely been noted in case reports [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/40,41\" class=\"abstract_t\">40,41</a>]. </p><p><a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">Azithromycin</a> is another possible alternative in exceptional cases, although there are no standard NCCLS antimicrobial susceptibility break points reported for salmonellae. Azithromycin resistance has been reported in <em>Salmonella choleraesuis</em> from Cambodia [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/42\" class=\"abstract_t\">42</a>].</p><p class=\"headingAnchor\" id=\"H1026982087\"><span class=\"h2\">Surgical management of complications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Extraintestinal nontyphoidal Salmonella infections generally warrant surgical drainage or debridement in addition to prolonged antimicrobial therapy. </p><p>In particular, for patients with endovascular infection, medical therapy alone is inadequate; surgery is required [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/43,44\" class=\"abstract_t\">43,44</a>]. Experienced vascular surgeons should be consulted. Because of the morbidity of extra-anatomic bypass, most experts perform in-situ debridement and grafting despite the risk of leak and relapsed infection. There are a variety of specific surgical approaches and grafts, depending on the site involved, intraoperative findings, and degree of debridement deemed necessary and achieved. Small surgical series of up to 26 patients have demonstrated a 60 to 100 percent survival rate [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/19,44,45\" class=\"abstract_t\">19,44,45</a>]. As an example, in a European retrospective registry of patients with mycotic aneurysm who underwent endovascular repair, among the 15 documented nontyphoidal Salmonella cases, four of six deaths occurred within 90 days, and the five-year survival among those surviving 90 days was 90 percent [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/46\" class=\"abstract_t\">46</a>]. This survival rate appeared superior to those with other infectious etiologies. </p><p>Antibiotics are an essential component of therapy, but the duration of therapy is debated. (See <a href=\"#H10\" class=\"local\">'Antibiotic selection'</a> above and <a href=\"#H13\" class=\"local\">'Extraintestinal focal infections and endovascular infection'</a> below.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Duration of antibiotic therapy</span></p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h3\">Bacteremia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal duration of antimicrobial therapy for nontyphoidal Salmonella bacteremia in the absence of extraintestinal focal infection depends upon the immune status of the host. A 14 day course of antimicrobial therapy for otherwise healthy individuals is likely appropriate. Patients with Salmonella gastroenteritis hospitalized with the suspicion of bacteremia should have blood cultures drawn and empiric treatment initiated while awaiting culture results. In such circumstances, prompt initiation of antibiotic therapy is of greater clinical importance than the possibility of prolonging fecal carriage, especially in older patients. (See <a href=\"topic.htm?path=nontyphoidal-salmonella-gastrointestinal-infection-and-carriage\" class=\"medical medical_review\">&quot;Nontyphoidal Salmonella: Gastrointestinal infection and carriage&quot;</a>.)</p><p>Longer courses of antimicrobial therapy (4 to 6 weeks) are warranted for patients with significant immunosuppression for whom recurrence or relapse is likely (eg, such as in the setting of <span class=\"nowrap\">HIV/AIDS,</span> solid organ transplant, or bone marrow transplant) [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/9,47,48\" class=\"abstract_t\">9,47,48</a>]. If infection <span class=\"nowrap\">and/or</span> bacteremia occurs at an immunological nadir in these patients, the infection may become established within the immunologically compromised reticuloendothelial system. Relapse may occur even after an asymptomatic interval and in the absence of a known focus of infection (such as osteomyelitis or an abnormal biliary or urinary system) [<a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/45\" class=\"abstract_t\">45</a>].</p><p>A period of suppressive therapy may also be appropriate for patients with significant immunosuppression, especially if relapse of bacteremia is documented after an initial successful treatment.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Extraintestinal focal infections and endovascular infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, complete debridement and drainage of soft tissue or visceral foci of infection should be followed by a minimum of 3 weeks of antimicrobial therapy if there are no clinical complications. Extraintestinal foci are virtually always seeded by bacteremic spread, so the issues discussed in the preceding section apply.</p><p>Longer courses of therapy (6 to 12 weeks) may be advisable depending upon the site, adequacy of surgical debridement achieved, presence of any prosthetic material (vascular grafts, joints, screws, plates, valves or other hardware), presence or absence remaining fluid collections or devitalized tissue, immunological status, and age of the patient. Duration of therapy should be commensurate with standard courses for the site of infection at a minimum; for example, a brain abscess, endocarditis, or osseous infection should be treated for at least 6 to 8 weeks if Salmonella are present.</p><p>Salmonella are hardy organisms that adapt to stressful environments and may be difficult to eradicate, especially if devitalized tissue or prosthetic material is present. Chronic suppressive therapy may be appropriate for patients with infection of prosthetic joints, heart valves, or vascular grafts where the potential consequences of relapsed infection may be dire. Reasonable suppressive regimens (depending on the sensitivity of the organism) include <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> (one DS tablet once daily), <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> (500 mg once daily) or <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> (750 mg once daily). Consultation with infectious disease expertise is recommended.</p><p class=\"headingAnchor\" id=\"H1615404491\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-acute-diarrhea-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Acute diarrhea in adults&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-acute-diarrhea-in-children\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Acute diarrhea in children&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=salmonellosis-salmonella-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Salmonellosis (Salmonella) (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bacteremia and other forms of extraintestinal Salmonella infection are serious complications that may not be suspected in the setting of mild primary infection. Factors affecting the incidence of bacteremia include Salmonella serotype, geographic location, time of year, and host factors including extremes of age and immunosuppressing conditions. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nontyphoidal Salmonella bacteremia can progress to development of infection at any site, including any visceral organ, long bones, joints, muscle, and central nervous system. After stool and blood, urinary isolates are encountered most frequently. Salmonella meningitis is a rare complication that typically occurs in neonates and children &le;1 year. (See <a href=\"#H7\" class=\"local\">'Extraintestinal focal infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Endovascular infection is a serious complication of nontyphoidal Salmonella bacteremia. The abdominal aorta (particularly the infrarenal aorta) is the most frequent site of infection. When a vascular focus of infection is suspected, CT or MRI with contrast should be performed. (See <a href=\"#H8\" class=\"local\">'Endovascular infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reasonable empiric antibiotics for treatment of nontyphoidal Salmonella bacteremia include fluoroquinolones (<a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> 400 mg intravenously twice daily or <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> 500 to 750 mg intravenously once daily) or third generation cephalosporins (<a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a> 1 to 2 g intravenously once daily or <a href=\"topic.htm?path=cefotaxime-drug-information\" class=\"drug drug_general\">cefotaxime</a> 2 g intravenously every eight hours). Stable patients may receive fluoroquinolones orally, as they have excellent oral bioavailability (ciprofloxacin 500 mg twice daily or levofloxacin 500 to 750 mg once daily). (See <a href=\"#H9\" class=\"local\">'Treatment'</a> above and <a href=\"#H10\" class=\"local\">'Antibiotic selection'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A 14 day course of antimicrobial therapy is likely adequate for otherwise healthy individuals with uncomplicated bacteremia accompanying gastroenteritis. Longer courses of antimicrobial therapy (4 to 6 weeks or more) are warranted for patients with significant immunosuppression for whom recurrence or relapse is likely. Suppressive therapy may also be appropriate for some patients, especially if relapse of bacteremia is documented after an initial successful treatment or prosthetic materials are present. (See <a href=\"#H12\" class=\"local\">'Bacteremia'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Extraintestinal nontyphoidal Salmonella infections generally require surgical drainage or debridement and prolonged antimicrobial therapy. (See <a href=\"#H1026982087\" class=\"local\">'Surgical management of complications'</a> above and <a href=\"#H13\" class=\"local\">'Extraintestinal focal infections and endovascular infection'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/1\" class=\"nounderline abstract_t\">Mandal BK, Brennand J. Bacteraemia in salmonellosis: a 15 year retrospective study from a regional infectious diseases unit. BMJ 1988; 297:1242.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/2\" class=\"nounderline abstract_t\">Ao TT, Feasey NA, Gordon MA, et al. Global burden of invasive nontyphoidal Salmonella disease, 2010(1). Emerg Infect Dis 2015; 21.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/3\" class=\"nounderline abstract_t\">Symmons DP, Silman AJ. The world of biologics. Lupus 2006; 15:122.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/4\" class=\"nounderline abstract_t\">Garcia-Vidal C, Rodr&iacute;guez-Fern&aacute;ndez S, Teij&oacute;n S, et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009; 28:331.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/5\" class=\"nounderline abstract_t\">Katsarolis I, Tsiodras S, Panagopoulos P, et al. Septic arthritis due to Salmonella enteritidis associated with infliximab use. Scand J Infect Dis 2005; 37:304.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/6\" class=\"nounderline abstract_t\">Gordon MA. Salmonella infections in immunocompromised adults. J Infect 2008; 56:413.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/7\" class=\"nounderline abstract_t\">Hung TY, Liu MC, Hsu CF, Lin YC. Rotavirus infection increases the risk of bacteremia in children with nontyphoid Salmonella gastroenteritis. Eur J Clin Microbiol Infect Dis 2009; 28:425.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/8\" class=\"nounderline abstract_t\">Dhanoa A, Fatt QK. Non-typhoidal Salmonella bacteraemia: epidemiology, clinical characteristics and its' association with severe immunosuppression. Ann Clin Microbiol Antimicrob 2009; 8:15.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/9\" class=\"nounderline abstract_t\">Gordon MA, Banda HT, Gondwe M, et al. Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence. AIDS 2002; 16:1633.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/10\" class=\"nounderline abstract_t\">Gordon MA, Graham SM, Walsh AL, et al. Epidemics of invasive Salmonella enterica serovar enteritidis and S. enterica Serovar typhimurium infection associated with multidrug resistance among adults and children in Malawi. Clin Infect Dis 2008; 46:963.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/11\" class=\"nounderline abstract_t\">Kariuki S, Revathi G, Kariuki N, et al. Characterisation of community acquired non-typhoidal Salmonella from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya. BMC Microbiol 2006; 6:101.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/12\" class=\"nounderline abstract_t\">Kariuki S, Revathi G, Kariuki N, et al. Invasive multidrug-resistant non-typhoidal Salmonella infections in Africa: zoonotic or anthroponotic transmission? J Med Microbiol 2006; 55:585.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/13\" class=\"nounderline abstract_t\">Siga&uacute;que B, Roca A, Mandomando I, et al. Community-acquired bacteremia among children admitted to a rural hospital in Mozambique. Pediatr Infect Dis J 2009; 28:108.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/14\" class=\"nounderline abstract_t\">Krumkamp R, Kreuels B, Sarpong N, et al. Association Between Malaria and Invasive Nontyphoidal Salmonella Infection in a Hospital Study: Accounting for Berkson's Bias. Clin Infect Dis 2016; 62 Suppl 1:S83.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/15\" class=\"nounderline abstract_t\">Biggs HM, Lester R, Nadjm B, et al. Invasive Salmonella infections in areas of high and low malaria transmission intensity in Tanzania. Clin Infect Dis 2014; 58:638.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/16\" class=\"nounderline abstract_t\">Chau JY, Tiffany CM, Nimishakavi S, et al. Malaria-associated L-arginine deficiency induces mast cell-associated disruption to intestinal barrier defenses against nontyphoidal Salmonella bacteremia. Infect Immun 2013; 81:3515.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/17\" class=\"nounderline abstract_t\">Uche IV, MacLennan CA, Saul A. A Systematic Review of the Incidence, Risk Factors and Case Fatality Rates of Invasive Nontyphoidal Salmonella (iNTS) Disease in Africa (1966 to 2014). PLoS Negl Trop Dis 2017; 11:e0005118.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/18\" class=\"nounderline abstract_t\">Zaidi E, Bachur R, Harper M. Non-typhi Salmonella bacteremia in children. Pediatr Infect Dis J 1999; 18:1073.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/19\" class=\"nounderline abstract_t\">Shimoni Z, Pitlik S, Leibovici L, et al. Nontyphoid Salmonella bacteremia: age-related differences in clinical presentation, bacteriology, and outcome. Clin Infect Dis 1999; 28:822.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/20\" class=\"nounderline abstract_t\">Jones TF, Ingram LA, Cieslak PR, et al. Salmonellosis outcomes differ substantially by serotype. J Infect Dis 2008; 198:109.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/21\" class=\"nounderline abstract_t\">Rodr&iacute;guez M, de Diego I, Mart&iacute;nez N, et al. Nontyphoidal Salmonella causing focal infections in patients admitted at a Spanish general hospital during an 11-year period (1991-2001). Int J Med Microbiol 2006; 296:211.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/22\" class=\"nounderline abstract_t\">Ramos JM, Aguado JM, Garc&iacute;a-Corbeira P, et al. Clinical spectrum of urinary tract infections due on nontyphoidal Salmonella species. Clin Infect Dis 1996; 23:388.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/23\" class=\"nounderline abstract_t\">Punpanich W, Netsawang S, Thippated C. Invasive salmonellosis in urban Thai children: a ten-year review. Pediatr Infect Dis J 2012; 31:e105.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/24\" class=\"nounderline abstract_t\">Sirinavin S, Chiemchanya S, Vorachit M. Systemic nontyphoidal Salmonella infection in normal infants in Thailand. Pediatr Infect Dis J 2001; 20:581.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/25\" class=\"nounderline abstract_t\">Molyneux EM, Mankhambo LA, Phiri A, et al. The outcome of non-typhoidal salmonella meningitis in Malawian children, 1997-2006. Ann Trop Paediatr 2009; 29:13.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/26\" class=\"nounderline abstract_t\">Keddy KH, Sooka A, Musekiwa A, et al. Clinical and Microbiological Features of Salmonella Meningitis in a South African Population, 2003-2013. Clin Infect Dis 2015; 61 Suppl 4:S272.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/27\" class=\"nounderline abstract_t\">Cohen PS, O'Brien TF, Schoenbaum SC, Medeiros AA. The risk of endothelial infection in adults with salmonella bacteremia. Ann Intern Med 1978; 89:931.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/28\" class=\"nounderline abstract_t\">Benenson S, Raveh D, Schlesinger Y, et al. The risk of vascular infection in adult patients with nontyphi Salmonella bacteremia. Am J Med 2001; 110:60.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/29\" class=\"nounderline abstract_t\">Hsu RB, Lin FY. Risk factors for bacteraemia and endovascular infection due to non-typhoid salmonella: a reappraisal. QJM 2005; 98:821.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/30\" class=\"nounderline abstract_t\">Cheng WL, Li CW, Li MC, et al. Salmonella infective endocarditis. J Microbiol Immunol Infect 2016; 49:313.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/31\" class=\"nounderline abstract_t\">Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25:1196.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/32\" class=\"nounderline abstract_t\">Leibovitz E. The use of fluoroquinolones in children. Curr Opin Pediatr 2006; 18:64.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/33\" class=\"nounderline abstract_t\">Stevenson JE, Gay K, Barrett TJ, et al. Increase in nalidixic acid resistance among non-Typhi Salmonella enterica isolates in the United States from 1996 to 2003. Antimicrob Agents Chemother 2007; 51:195.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/34\" class=\"nounderline abstract_t\">Humphries RM, Fang FC, Aarestrup FM, Hindler JA. In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards. Clin Infect Dis 2012; 55:1107.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/35\" class=\"nounderline abstract_t\">Lee HY, Su LH, Tsai MH, et al. High rate of reduced susceptibility to ciprofloxacin and ceftriaxone among nontyphoid Salmonella clinical isolates in Asia. Antimicrob Agents Chemother 2009; 53:2696.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/36\" class=\"nounderline abstract_t\">Angelo KM, Reynolds J, Karp BE, et al. Antimicrobial Resistance Among Nontyphoidal Salmonella Isolated From Blood in the United States, 2003-2013. J Infect Dis 2016; 214:1565.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/37\" class=\"nounderline abstract_t\">Iwamoto M, Reynolds J, Karp BE, et al. Ceftriaxone-Resistant Nontyphoidal Salmonella from Humans, Retail Meats, and Food Animals in the United States, 1996-2013. Foodborne Pathog Dis 2017; 14:74.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/38\" class=\"nounderline abstract_t\">Jean SS, Lee YT, Guo SM, Hsueh PR. Recurrent infections caused by cefotaxime- and ciprofloxacin-resistant Salmonella enterica serotype choleraesuis treated successfully with imipenem. J Infect 2005; 51:e163.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/39\" class=\"nounderline abstract_t\">Li WC, Huang FY, Liu CP, et al. Ceftriaxone resistance of nontyphoidal Salmonella enterica isolates in Northern Taiwan attributable to production of CTX-M-14 and CMY-2 beta-lactamases. J Clin Microbiol 2005; 43:3237.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/40\" class=\"nounderline abstract_t\">Miriagou V, Tzouvelekis LS, Rossiter S, et al. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob Agents Chemother 2003; 47:1297.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/41\" class=\"nounderline abstract_t\">Day MR, Meunier D, Doumith M, et al. Carbapenemase-producing Salmonella enterica isolates in the UK. J Antimicrob Chemother 2015; 70:2165.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/42\" class=\"nounderline abstract_t\">Vlieghe ER, Phe T, De Smet B, et al. Azithromycin and ciprofloxacin resistance in Salmonella bloodstream infections in Cambodian adults. PLoS Negl Trop Dis 2012; 6:e1933.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/43\" class=\"nounderline abstract_t\">Oskoui R, Davis WA, Gomes MN. Salmonella aortitis. A report of a successfully treated case with a comprehensive review of the literature. Arch Intern Med 1993; 153:517.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/44\" class=\"nounderline abstract_t\">Lee CH, Hsieh HC, Ko PJ, et al. Treatment of infected abdominal aortic aneurysm caused by Salmonella. Ann Vasc Surg 2014; 28:217.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/45\" class=\"nounderline abstract_t\">Chen PL, Chang CM, Wu CJ, et al. Extraintestinal focal infections in adults with nontyphoid Salmonella bacteraemia: predisposing factors and clinical outcome. J Intern Med 2007; 261:91.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/46\" class=\"nounderline abstract_t\">S&ouml;relius K, Mani K, Bj&ouml;rck M, et al. Endovascular treatment of mycotic aortic aneurysms: a European multicenter study. Circulation 2014; 130:2136.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/47\" class=\"nounderline abstract_t\">Hsu RB, Lin FY. Nontyphoid Salmonella infection in heart transplant recipients. Am J Med Sci 2008; 336:393.</a></li><li><a href=\"https://www.uptodate.com/contents/nontyphoidal-salmonella-bacteremia/abstract/48\" class=\"nounderline abstract_t\">Dhar JM, al-Khader AA, al-Sulaiman M, al-Hasani MK. Non-typhoid Salmonella in renal transplant recipients: a report of twenty cases and review of the literature. Q J Med 1991; 78:235.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3126 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H14\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Incidence</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Risk factors</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">MICROBIOLOGY AND DIAGNOSIS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">COMPLICATIONS</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Extraintestinal focal infection</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Endovascular infection</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">TREATMENT</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">Antibiotic selection</a></li><li><a href=\"#H1026982087\" id=\"outline-link-H1026982087\">Surgical management of complications</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Duration of antibiotic therapy</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">- Bacteremia</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">- Extraintestinal focal infections and endovascular infection</a></li></ul></li></ul></li><li><a href=\"#H1615404491\" id=\"outline-link-H1615404491\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H15836061\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-microbiology-clinical-manifestations-and-diagnosis-of-enteric-typhoid-and-paratyphoid-fever\" class=\"medical medical_review\">Epidemiology, microbiology, clinical manifestations, and diagnosis of enteric (typhoid and paratyphoid) fever</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fluoroquinolones\" class=\"medical medical_review\">Fluoroquinolones</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gram-negative-bacillary-meningitis-treatment\" class=\"medical medical_review\">Gram-negative bacillary meningitis: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nontyphoidal-salmonella-gastrointestinal-infection-and-carriage\" class=\"medical medical_review\">Nontyphoidal Salmonella: Gastrointestinal infection and carriage</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nontyphoidal-salmonella-microbiology-and-epidemiology\" class=\"medical medical_review\">Nontyphoidal Salmonella: Microbiology and epidemiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-salmonella-gastroenteritis\" class=\"medical medical_review\">Pathogenesis of Salmonella gastroenteritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=salmonellosis-salmonella-the-basics\" class=\"medical medical_basics\">Patient education: Salmonellosis (Salmonella) (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-acute-diarrhea-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Acute diarrhea in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-acute-diarrhea-in-children\" class=\"medical medical_society_guidelines\">Society guideline links: Acute diarrhea in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-enteric-typhoid-and-paratyphoid-fever\" class=\"medical medical_review\">Treatment and prevention of enteric (typhoid and paratyphoid) fever</a></li></ul></div></div>","javascript":null}